"Business Report" also mentioned Sanofi SA (Euronext: SAN; NYSE: SNY), Baxter International Inc. (NYSE: BAX), and Reckitt-Benckiser plc (LSE: RB). 
Share:  <span class="sent">"Business Report" also mentioned Sanofi SA (Euronext: SAN; NYSE: SNY), Baxter International Inc. (NYSE: BAX), and Reckitt-Benckiser plc (LSE: RB).</span> Tweet this   read full story

With Sanofi ($SNY) riding the tail end of the latest earnings wave, its sales and profits shortfall feels like more of the same. It hasn't been a good quarter for Big Pharma, and Sanofi's results fall right in line with the rest. Its 5.3% sales drop was less severe than most, while its profits suffered a bit more, with a 34% decline. 
Share:  With Sanofi ($<span class="company">SNY</span>) riding the tail end of the latest earnings wave, its sales and profits shortfall feels like more of the same. It hasn't been a good quarter for Big Pharma, and Sanofi's results fall right in line with the rest. Its 5.3% sales drop was less severe than most, while its profits suffered a bit more, with a 34% decline. Tweet this   read full story

Sanofi SA ( EPA: SAN) ‘s stock had its "buy" rating reiterated by investment analysts at Deutsche Bank in a note issued to investors on Thursday, Analyst Ratings. 
Share:  <span class="sent">Sanofi SA ( EPA: SAN) ‘s stock had its "buy" rating reiterated by investment analysts at Deutsche Bank in a note issued to investors on Thursday, Analyst Ratings.</span> Tweet this   read full story

PARIS French drugs giant Sanofi SA ( SNY) Thursday said it expects a return to growth later in the year as the effects of lost of patent protection on key drugs eases and new products come through its pipeline."The Group expects to resume growth in the second half," Sanofi Chief Executive Chris Viehbacher said, presenting a sharp drop in company's first quarter earnings. Still, he noted double digit growth, percentage wise over the quarter from three businesses the company is banking on for future growth: diabetes, vaccines and the biotech company Genzyme. Mr. Viehbacher added that early launch trends for multiple sclerosis treatment Aubagio and emergency allergy treatment Auvi Q in the U. S are "encouraging." 
Share:  PARIS French drugs giant Sanofi SA ( SNY) Thursday said it expects a return to growth later in the year as the effects of lost of patent protection on key drugs eases and new products come through its pipeline."The <span class="sent">Group expects to resume growth in the second half," Sanofi Chief Executive Chris Viehbacher said, presenting a sharp drop in company's first quarter earnings.</span> Still, he noted double digit growth, percentage wise over the quarter from three businesses the company is banking on for future growth: diabetes, vaccines and the biotech company Genzyme. Mr. Viehbacher added that early launch trends for multiple sclerosis treatment Aubagio and emergency allergy treatment Auvi Q in the U. S are "encouraging." Tweet this   read full story

The new study, looking only at those patients, will start by the third quarter of 2013, Lilly said in December. Sanofi Chief Executive Officer Chris Viehbacher said earlier this month the French drugmaker won't pursue an Alzheimer's treatment because the science isn't advanced enough to justify the cost. The first Alzheimer's drugs, if successful, would lead to a market worth $20 billion, Barbara Ryan, a former Deutsche Bank analyst estimated last year. . 
Share:  The new study, looking only at those patients, will start by the third quarter of 2013, Lilly said in December. <span class="sent"><span class="company">Sanofi</span> Chief Executive Officer <span class="analyst">Chris Viehbacher</span> said earlier this month the French drugmaker won't pursue an Alzheimer's treatment because the science isn't advanced enough to justify the cost.</span> The first Alzheimer's drugs, if successful, would lead to a market worth $20 billion, Barbara Ryan, a former Deutsche Bank analyst estimated last year. . Tweet this   read full story